NJK14047

®

MedChemExpress

BIOLOGICAL ACTIVITY		
Description	NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage- induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice ^[1] .	
In Vitro	NJK14047 (3-10 μM) inhibits expressions of inflammatory cytokines IL-1β, TNF-α, IL-6, IL-17A, RANKL, and MMP-3 in Lipopolysaccharid (HY-D1056) stimulated human SW982 synovial cells ^[1] . NJK14047 (3-10 μM) inhibits the differentation of naive CD4 ⁺ T cells into Th1, Th2 and Th17 cells in a dose-dependent manner [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	NJK14047 (2.5 mg/kg, i.p. for 7-21 days) ameliorates the collage-induced rehumatoid arthritis (CIA) in DBA-1J mice and Imiquimod (HY-B0180)-induced psoriasis (IIP) in BALB/c mice, suppresses the cytokines expressions of Th1, Th2, Th17 and Treg ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	collage-induced rehumatoid arthritis in DBA-1J mice and imiquimod-induced psoriasis in BALB/c mice ^[1]
	Dosage:	2.5 mg/kg
	Administration:	i.p. for 7 days for IIP-administrated BALB/c mice, i.p. for 21 days for CIA-administrated CBA-1J mice
	Result:	Ameliorated the collage-induced arthritis and CIA caused cartilage damage, inflammation, pannus formation, bone corrosion, and synovial hyperplasia. Ameliorated the imiquimod induced psoriasis and IIP caused keratinocyte proliferation.

REFERENCES

[1]. Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA